Innoviva (INVA) Competitors $17.26 +0.01 (+0.03%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. LGND, FOLD, CLDX, BCRX, MNKD, NVAX, OPK, DVAX, ZBIO, and GERNShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "biotechnology" industry. Innoviva vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics BioCryst Pharmaceuticals MannKind Novavax OPKO Health Dynavax Technologies Zenas BioPharma Geron Ligand Pharmaceuticals (NASDAQ:LGND) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do analysts prefer LGND or INVA? Ligand Pharmaceuticals currently has a consensus target price of $176.50, suggesting a potential downside of 3.91%. Innoviva has a consensus target price of $37.60, suggesting a potential upside of 117.91%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Innoviva 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more risk & volatility, LGND or INVA? Ligand Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Does the media refer more to LGND or INVA? In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 2 mentions for Innoviva. Ligand Pharmaceuticals' average media sentiment score of 0.88 beat Innoviva's score of 0.79 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of LGND or INVA? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, LGND or INVA? Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M21.54-$4.03M-$4.00-45.92Innoviva$358.71M3.03$23.39M$0.3155.66 Is LGND or INVA more profitable? Innoviva has a net margin of 10.44% compared to Ligand Pharmaceuticals' net margin of -40.44%. Innoviva's return on equity of 18.67% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-40.44% -9.21% -8.09% Innoviva 10.44%18.67%9.92% SummaryInnoviva beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09B$267.57B$6.11B$10.54BDividend YieldN/A2.62%5.73%4.78%P/E Ratio55.6830.8384.1027.08Price / Sales3.035.15608.24131.39Price / Cash5.0814.4337.8662.13Price / Book1.5619.5712.246.58Net Income$23.39M$8.49B$3.32B$276.75M7 Day Performance-0.55%-0.83%0.73%0.88%1 Month Performance-10.96%2.64%7.97%4.10%1 Year Performance-14.45%-4.73%71.13%35.25% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva4.6676 of 5 stars$17.26+0.0%$37.60+117.9%-14.6%$1.09B$358.71M55.68100LGNDLigand Pharmaceuticals3.8779 of 5 stars$179.89+1.2%$176.50-1.9%+68.7%$3.48B$167.13M-44.9780News CoverageFOLDAmicus Therapeutics4.421 of 5 stars$8.18-1.4%$15.78+92.9%-22.8%$2.56B$528.29M-68.16480Positive NewsCLDXCelldex Therapeutics1.6669 of 5 stars$27.13+1.3%$43.78+61.4%-10.7%$1.78B$7.02M-9.01150Trending NewsAnalyst ForecastGap UpBCRXBioCryst Pharmaceuticals4.3641 of 5 stars$7.04-2.5%$16.30+131.5%-11.2%$1.52B$450.71M-39.11530Trending NewsAnalyst ForecastAnalyst RevisionMNKDMannKind3.9193 of 5 stars$5.10+4.5%$10.86+112.9%-20.5%$1.50B$285.50M46.37400NVAXNovavax4.1603 of 5 stars$8.62+3.5%$12.33+43.1%-16.5%$1.35B$682.16M3.781,990Gap DownOPKOPKO Health4.1034 of 5 stars$1.51flat$2.63+73.8%+0.7%$1.20B$713.10M-6.042,997DVAXDynavax Technologies4.5623 of 5 stars$10.01+0.5%$24.33+143.1%-11.2%$1.17B$277.25M-21.76350Positive NewsZBIOZenas BioPharma2.0566 of 5 stars$26.54-0.2%$38.33+44.4%N/A$1.12B$5M-7.48N/AInsider TradeGERNGeron2.8042 of 5 stars$1.27-3.1%$3.79+198.1%-70.5%$835.80M$76.99M-9.7770News Coverage Related Companies and Tools Related Companies Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Novavax Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
